BNR Stock Summary and Trading Ideas (Burning Rock Biotech Limited - American Depositary Shares | NASDAQ:BNR)

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Burning Rock Biotech Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol BNR.

As of September 9, 2026, BNR stock price climbed to $11.99 with 43,458 million shares trading.

BNR has a market cap of $126.45 million. This is considered a Micro Cap stock.

In the last 3 years, BNR traded as high as $41.72 and as low as $2.18.

The top ETF exchange traded funds that BNR belongs to (by Net Assets): PGJ.

BNR has outperformed the market in the last year with a price return of +32.3% while the SPY ETF gained +18.7%. BNR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +32.2% and +22.3%, respectively, while the SPY returned +3.4% and -0.5%, respectively.

BNR support price is $9.57 and resistance is $11.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BNR shares will trade within this expected range on the day.